A biocomplex to repair experimental critical size defects associated with photobiomodulation therapy

Daniela Vieira Buchaim\textsuperscript{1,2,3*}, Jesus Carlos Andreo\textsuperscript{4}, Karina Torres Pomin\textsuperscript{1,4}, Benedito Baraviera\textsuperscript{3,5,6}, Rui Seabra Ferreira Júnior\textsuperscript{3,5,6}, Marco Antonio Hungaro Duarte\textsuperscript{2,6}, Murilo Priori Alcalde\textsuperscript{9}, Carlos Henrique Bertoni Reis\textsuperscript{1}, Daniel de Bortoli Teixeira\textsuperscript{1}, Cleuber Rodrigo de Souza Bueno\textsuperscript{4}, Cláudia Rucco Penteado Detregiachi\textsuperscript{7}, Adriano Cressoni Araujo\textsuperscript{1}, Rogério Leone Buchaim\textsuperscript{3,4,8},

\textsuperscript{1}Graduate Program in Structural and Functional Interactions in Rehabilitation, University of Marilia (UNIMAR), Marília, SP, Brazil.
\textsuperscript{2}Medical School, University Center of Adamantina (UniFAI), Adamantina, SP, Brazil.
\textsuperscript{3}Center for the Study of Venoms and Venomous Animals (CEVAP), São Paulo State University (UNESP), Botucatu, SP, Brazil.
\textsuperscript{4}Department of Biological Sciences (Anatomy), Bauru School of Dentistry, University of São Paulo (USP), Bauru, SP, Brazil.
\textsuperscript{5}Graduate Program in Clinical Research, Center for the Study of Venoms and Venomous Animals (CEVAP), São Paulo State University (UNESP), Botucatu, SP, Brazil.
\textsuperscript{6}Graduate Program in Tropical Diseases, Botucatu Medical School (FMB), São Paulo State University (UNESP), Botucatu, SP, Brazil.
\textsuperscript{7}Department of Dentistry, Endodontics and Dental Materials, Bauru School of Dentistry, University of São Paulo (USP), Bauru, SP, Brazil.
\textsuperscript{8}Graduate Program in Applied Dental Sciences, Bauru School of Dentistry, University of São Paulo (USP), Bauru, SP, Brazil.
\textsuperscript{9}Department of Health Science, Unisagrado University Center, Bauru, SP, Brazil.

Keywords:
Bone regeneration
Biomaterials
Bone substitutes
Fibrin sealant
Low-level laser therapy
Photobiomodulation therapy

Abstract

Background: The association of scaffolds to repair extensive bone defects can contribute to their evolution and morphophysiological recomposition. The incorporation of particulate biomaterials into three-dimensional fibrin bioproducts together with photobiomodulation therapy (PBM) has potential and can improve regenerative medicine procedures. The objective of this experiment was to evaluate the effects of PBM therapy on critical size defects filled with xenogenic bone substitute associated with fibrin biopolymer.

Methods: A critical defect of 8 mm was performed in 36 Wistar male adult rats that were divided into four groups. Groups BC and BC-PBM were defined as controls with defects filled by a clot (without or with PBM, respectively) and groups XS and XS-PBM that comprised those filled with biocomplex Bio-Oss\textsuperscript{TM} in association with fibrin biopolymer. PBM was applied immediately after the surgery and three times a week every other day, with the parameters: wavelength of 830 nm, energy density 6.2 J/cm\textsuperscript{2}, output power 30 mW, beam area of 0.116 cm\textsuperscript{2}, irradiance 0.258,62 W/cm\textsuperscript{2}, energy/point 0.72 J, total energy 2.88 J. Fourteen and 42 days after the surgery, animals were euthanatized and subjected to microtomography, qualitative and quantitative histological analysis.
Background

Most bone defects such as fractures have the capacity for spontaneous regeneration, which leads to treatment by conventional therapies. The repair process begins with the formation of the clot, accompanied by an inflammatory process with proliferation of granulation tissue. With the formation of a bone callus and organization of the new bone in lamellae, the process can progress to complete remodeling and total repair. However, in cases of large defects, fractures with loss of segment and resection of tumors, the use of grafts (autografts, allografts and xenografts) or bone substitutes may be indicated to contribute to healing [1,2]. More than two million grafting procedures are performed worldwide per year, the second most frequent tissue transplant after blood transfusion [3,4].

The autologous graft is still considered the gold standard, as it has the necessary properties for bone regeneration, in terms of combined osteoconduction, osteoinduction and osteogenesis [5,6]. However, its availability is limited and morbidity at the donor site demonstrates the need to develop alternative materials. Tissue engineering methods [7] are used to develop new bone substitutes that restore, improve or prevent the deterioration of compromised tissue function [8–11]. The development of biomaterials for grafts with biocompatibility, biodegradability and osteoconductibility properties, allow the proliferation of osteoblasts within an adequate three-dimensional structure (scaffolds), which provide ideal conditions for bone neoformation [12,13].

Bio-Oss™ is a mineral bovine hydroxyapatite with chemical composition similar to natural mineral bone. It has satisfactory osteoconductive properties as it allows the neoformation of capillaries, perivascular tissue and migration of cells from the recipient bed through a three-dimensional structure. It does not induce a local or systemic immune response due to the complete elimination of bovine bone proteins carried out by a process of physical sterilization and by procedures [13–16]. Biomaterials in the form of small granules are commonly used in clinical practice. However, these granules are difficult to retain in the recipient bed, mainly due to the various conformations of defects and also due to bleeding at the site [17].

To solve this problem, biocomplexes can be used by associating the biomaterial with platelet-rich plasma (PRP) or fibrin (PRF), as well as fibrin scaffolds, to form a moldable material preventing the dispersion of the granules [18–22]. Engineered biocomplexes also can be made of mesenchymal-derived cells and a 3D structure as scaffold, for defect repair or transplantation purpose [23]. Fibrin sealants are three-dimensional biological matrices that provide support, fixation and cell growth, as well as the presence of various growth factors and angiogenesis, important properties that qualify them as candidates to integrate a biocomplex [24–26].

The heterologous fibrin sealant, also known as fibrin biopolymer, is a genuinely Brazilian product derived from animals, biocompatible, and of low production cost in addition to adhesive, sealant, hemostatic, scaffold, and drug delivery properties [27–33]. This new fibrin sealant was evaluated in phase I/II clinical trial and have showed be safe, non-immunogenic in addition to good preliminary efficacy [34,35].

In order to recover the compromised anatomy and function, together with grafts, complementary therapies can be used to reduce bone healing time and, eventually, reduce complications in the regenerative process. Among them, photobiomodulation (PBM) therapy, using low-level laser (LLLT), stands out due to its satisfactory effects on bone metabolism and repair, with great osteogenic potential, as it is a non-invasive and relatively inexpensive method [36,37].

There are few studies using fibrin as scaffold for biomaterials, especially with the heterologous biopolymer, in association with the PBM protocol used in this experiment. Therefore, the objective of this experimental protocol was to evaluate the effects of photobiomodulation on critical size defects filled with a biocomplex composed of xenogenic bone substitute associated with fibrin biopolymer.

Methods

Ethical aspects of research

The study was conducted according to the guidelines of the Declaration of Helsinki, and was approved by the Institutional Review Board of the Ethics Committee on Teaching and Research in Animals of the Bauru School of Dentistry, University of São Paulo (FAB-USP), Brazil, Protocol CEEPA n. 019/2016, dated October 21, 2016.

Selection and maintenance of animals

Thirty-six male Wistar rats (Rattus norvegicus) were used, aged 90 days, body mass of approximately 390g, from the bioterium of the University of São Paulo (Ribeirão Preto, SP, Brazil) and kept

Results: The BC-PBM and XS-PBM groups had a similar evolution in the tissue repair process, with a higher density of the volume of new formed bone in relation to the groups without PBM ($p = 0.04086; p = 0.07093$, respectively). Intense vascular proliferation and bone deposition around the biomaterial particles were observed in the animals of the groups in which biocomplex was applied (XS and XS-PBM).

Conclusion: PBM therapy allowed an improvement in the formation of new bone, with a more organized deposition of collagen fibers in the defect area. Biocomplex favored the insertion and permanence of the particulate material in bone defects, creating a favorable microenvironment for accelerate repair process.
in the bioterium of the Bauru School of Dentistry (University of São Paulo, Bauru, SP, Brazil).

The animals were kept in conventional cages containing 4 animals each, with feeders and drinking fountains ad libitum (Nuvilab™ rat chow, Nuvital, Colombo, PR, Brazil), in an air-conditioned environment, air exhaustion, period light-dark 12/12 hours, temperature 22°C ± 2°C, humidity 60% ± 10, max noise 70 dB.

Initially, the animals went through a supervised quarantine period to reach the desired age and weight, to verify possible changes in behavior and feed consumption. The inclusion criteria used were: males, healthy and young adults to avoid interference from hormonal factors, to ensure metabolic and physiological conditions.

Randomization of experimental groups
The rats were randomly assigned to four groups according to the type of filling of the defect, and submitted to treatment by PBM: blood clot group (BC, \(n=8\)), defect filled by blood clot obtained from the animal itself by cardiac puncture; blood clot with PBM group (BC-PBM, \(n=8\)), defect filled by blood clot associated with PBM; xenogeneic bone graft + fibrin biopolymer scaffold group (XS, \(n=10\)), defect filled by the association of the xenogenic biomaterial with the fibrin biopolymer; xenogeneic bone graft + fibrin biopolymer scaffold with PBM group (XS-PBM, \(n=10\)), defect filled by the association of the xenogenic biomaterial with the fibrin biopolymer associated with PBM therapy.

Scaffolds

Xenogeneic bone graft
The Bio-Oss™ bone substitute (Geistlich Pharma AG, Wolhusen, Switzerland Wolhusen, Switzerland) that was used in this experimental protocol had granules of dimensions between 0.25-1 mm, packaged in a 2 g bottle, batch 81600891, ANVISA Registry nº 80696930002 (Figure 1).

Heterologous fibrin biopolymer
Fibrin biopolymer was kindly provided by the Center for the Study of Venoms and Venomous Animals (CEVAP) at the São Paulo State University Júlio de Mesquita Filho (UNESP), Botucatu (São Paulo, Brazil), whose components and application formula are available at Ferreira Jr. et al. [38] and others [27,39].

The bioproduct consists of a thrombin-like enzyme purified from Crotalus durissus terrificus snake venom (component 1), the diluent comprises calcium chloride; and component 2 containing fibrinogen-rich cryoprecipitate extracted from Bubalus bubalis buffalo blood. All vials were stored in a freezer at ~20°C until use [38] (Figure 1).

Figure 1. Schematic drawing of the production of the scaffolds used in this experimental protocol, the xenogeneic bone graft (Bio-Oss™) and the fibrin biopolymer (CEVAP/UNESP). In the center of the image, the incorporation of the granular particles of the biomaterial into the fibrin biopolymer is represented, forming the biocomplex that was the filling material for bone defects of 8 mm in diameter in the center of the parietal bones of all animals.
Experimental surgery

Surgical procedures were performed at the Mesoscopy of the Anatomy Laboratory of the Department of Biological Sciences at FOB-USP. For surgery, the animals were submitted to general anesthesia by intramuscular application of the combination of ketamine hydrochloride 50 mg/kg of animal weight (Dopalen™, Seva Animal Health, Paulínia, SP, Brazil) and xylazine 10 mg/kg of animal weight (Anasedan™, Seva Animal Health, Paulínia, SP, Brazil), in the proportion of 1:1.

Then, trichotomy was performed, with the aid of a hair trimmer (Philips™ Multigroom QG3250, SP, Brazil), in the region of the frontal and parietal bones. In the animals of the BC and BC-PBM groups, cardiac puncture was performed by removing 1.5 to 2 mL of blood from each animal with a 5 mL syringe. The collected blood was transferred to a microtube to form the clot and be deposited in the bone defect. Antisepsis of the trichotomized region, including the coat around that area, was performed with a 10% topical solution of Polyvinyl Pyrrolidone Iodine PVPI (Povidine™, Vic Pharma, Taquaritinga, SP, Brazil). The surgical procedure was always performed by the same surgeon.

The animals were fixed to the operating table, positioned in the prone position. Then, a 4 cm semi-lunar incision was made with a carbon steel scalpel blade No. 15 (Embramax™, SP, Brazil) in the tegument and the periosteum was carefully detached with the aid of the syndesmotome and folded together with the other tissues, exposing the outer surface of the parietal bones. A circular osteotomy of 8.0 mm in external diameter was performed on the parietal bones, involving the sagittal suture, with the aid of the trephine drill (Neodent™, Curitiba, PR, Brazil) adapted to the electric contra-angle (Driller™, SP, Brazil) at low speed (1500 rpm), under constant and abundant sterile saline irrigation (0.9% saline) to prevent osteonecrosis by thermal action.

In all animals of groups XS and XS-PBM the defects were filled with fibrin biopolymer and Bio-Oss™, with the biomaterial having a weight of approximately 0.03 mg. After complete polymerization of the biopolymer with the xenograft, the resulting biocomplex was transferred to the defect site without putting pressure on the brain. The proportion used (1:1:2 - 20 µL component 1, 20 µL diluent and 40 µL component 2) was in accordance with the recommendations of the producers and the amount readjusted according to the research needs (Figure 2).

The tissues of the surgical area were repositioned, taking care that the periosteum covered the cavity, and then the integument (simple stitches) was sutured with 5-0 silk thread (Ethicon™, Johnson and Johnson Company, SP, Brazil). The region was carefully cleaned with gauze moistened with topical antiseptic, 2% chlorhexidine (Riohex™, Rioquimica, São José do Rio Preto, SP, Brazil).

Figure 2. Experimental design. Thirty-six male Wistar rats underwent a critical bone defect in the center of the parietal bones with a no. 8 drill. In 16 animals, the defect was filled with a blood clot from an intracardiac puncture. In 20 animals, a biocomplex formed by the granulated biomaterial Bio-Oss™ was incorporated into the fibrin biopolymer (CEVAP/UNESP). The groups were constituted as follows: blood clot group (BC, n = 8), defect filled with blood clot obtained from the animal itself by cardiac puncture; blood clot with PBM group (BC-PBM, n = 8), defect filled with blood clot associated with PBM; xenogeneic bone graft + fibrin biopolymer scaffold group (XS, n = 10), defect filled with the association of the xenogenic biomaterial with the fibrin biopolymer; xenogeneic bone graft + fibrin biopolymer scaffold with PBM group (XS-PBM, n = 10), defect filled with the association of the xenogenic biomaterial with the fibrin biopolymer associated with PBM. PBM was performed at four points in the form of a cross, for 24 seconds at each point, using the GaAlAs laser (Ibramed™).
The animals were placed in the lateral decubitus position in cages, close to a light for adequate room temperature during all anesthetic recovery. Immediately after the surgical procedures, the animals received the analgesic paracetamol (Generic Medication, Medley™, Suzano, SP, Brazil) at a dose of 200 mg/kg, 6 drops/animal dissolved in the water available in the drinking fountain.

**Photobiomodulation (PBM) therapy**

For PBM therapy, the animals were immobilized manually and carefully, making it unnecessary to use anesthetic during application. All animals in groups BC-PBM and XS-PBM were submitted to treatment with laser GaAlAs (gallium–aluminum–arsenide, Ibramed Laserpulse™, Amparo, SP, Brazil). The PBM protocol, used for tissue repair in previous experiments [20,29,40–44], is described in Table 1.

The treatment started in the immediate postoperative period and three times a week every other day until the period corresponding to euthanasia (Figure 2). The laser beam emissions were calibrated on the device itself.

**Surgical procedure for tissue collection**

After the periods of 14 and 42 days post-surgery, five animals from each group XS and XS-PBM and four animals from each group BC and BC-PBM, by period, were euthanized by the overdose method of general anesthetic (triple dose) used for surgery. Then, the defect region of each animal was removed, preserving the supraperiosteal soft tissues and fixed in a 10% formalin solution in pH 7.2 phosphate buffer for one week, and later, for examination on the microtomograph.

### Table 1. Details of the parameters used for PBM therapy.

| Parameter                        | Description |
|----------------------------------|-------------|
| Type of laser                    | Infrared (GaAlAs*) |
| Wavelength (nm)                  | 830         |
| Output power (mW)                | 30          |
| Beam area (cm²)                  | 0.116       |
| Irradiance (W/cm²)               | 0.258,62    |
| Treatment time per point of irradiation (s) | 24        |
| Number of irradiation points     | 4           |
| Energy per point (Joule – J)     | 0.72        |
| Total energy applied (Joule – J) | 2.88        |
| Energy density per point of irradiation (J/cm²) | 6.20 |
| Emission mode                    | Continuous  |
| Application mode                 | Device held in contact mode and perpendicular to the skull |
| Frequency of treatment           | 3 times a week every other day |

*Gallium-aluminum-arsenide.
After complete demineralization, they were dehydrated in an increasing series of ethyl alcohol, diaphanized in xylol and included in Histosec™ processed paraffin (Merck, Hessen, Germany). Coronal slices were made, semi-series considering the central region of the defect with the aid of the semi-automatic microtome Leica™ RM2245 (Leica Biosystems, Wetzlar, Germany) and 5 µm thick slices (6 slides with 4 cuts each) were obtained for hematoxylin-eosin (HE) staining and Picrosirius-red.

In the slides with picrosirius-red, the quality of the new bone formed in the defects was evaluated by structured collagen orientation. Thus, the images were obtained using the Leica DFC 310FX high resolution digital camera (Leica™, Microsystems, Wetzlar, Germany) connected to the Leica DM IRBE confocal laser microscope and LAS 4.0.0 capture system (Leica™, Microsystems, Heerbrugg, Switzerland ). Each type of fiber by color was evaluated using the analysis software of Axio Vision Rel. 4.8 Ink (Carl Zeiss™ MicroImaging GmbH, Jena, Germany). The interlaced bone was recognized for its random and unorganized fibrillar pattern, usually with polarization colors varying between red-orange (immature bone tissue) and lamellar bone (light green/yellow), depending on the width of the fiber.

In the HE slides, the entire extension of the defect was considered to assess the bone repair pattern in all groups. Thus, it was possible to analyze in each defect the presence of granulation tissue, inflammatory infiltrate, the presence and quality of immature or mature/lamellar bone and the degree of filling of the newly formed tissue.

### Histomorphometric analysis

Four semi-serial sections of the surgical bed for each defect were evaluated using an Olympus™ BX50 light microscope (Olympus, Tokyo, Japan) and the photographs were captured in 4× lenses with the attached digital camera (Olympus™ DP 71, Tokyo, Japan) using the DP Controller 3.2.1.276 image capture software (Olympus™, Tokyo, Japan) with image size specifications of 4080x3072 pixels and spot 30%.

The volume density (VVi) was defined as the volume fraction occupied by a given constituent (graft, inflammatory infiltrate, connective tissue, bone tissue and bone marrow) of the whole (defect with the graft + reaction tissue), and can be obtained in histological sections as area fraction i.e VVi = Ai / A. Thus, the assessment of volume density followed the protocol described below. After capturing images covering the entire defect using the 4x lens, the reconstruction of the entire defect was performed in the Adobe Photoshop CS6 program. Then, the entire defect was evaluated in the image analysis program AxioVision, where the total area analyzed (A) and the area occupied by each constituent in the defect (Ai) were determined by the PIXEL unit of measurement. VVi of each type of structure was calculated by the relation: VVi = AAi = Ai / A.100 [45].

### Statistical analysis

The data obtained for the percentage of new bone formed were subjected to analysis of variance (ANOVA), in order to verify the existence of effects of the different groups tested in each evaluated period. The homogeneity of the variances and normality of the residues, necessary assumptions for the conduction of ANOVA, were tested, respectively, by the Shapiro-Wilk and Bartlett tests. Subsequently, the averages were compared using the Tukey test (p ≤ 0.05). The effect of the period evaluated in each tested group was compared by Student’s t test (p ≤ 0.05). All analyzes were conducted using the R software (R Core Team, 2017).

### Results

#### Microtomographic evaluation

### Descriptive analysis of 2D images obtained for the different experimental groups

The descriptive analysis of the microtomographic images in the periods of 14 and 42 days (Figures 3 and 4, respectively) was performed in the 2D plane (view of the transaxial and coronal sections), with the purpose of analyzing the evolution of the repair in the studied periods, the performance and maintenance of the biocomplex and, consequently, new bone formation.

In all evaluated defects, bone formation occurred centripetally, from the edges towards the center of the defect. In the BC and BC-PBM groups, although there was a continuous increase in bone neoformation during the experimental periods (Figures 3A-3B, 4A-4B and 3A1-3B1, 4A1-4B1), and in no animal did the complete defect close (yellow arrow) and the thickness of the bone formed was restricted to less than 1/3 of the original bone block surgically removed.

In the defect filled with the biocomplex (Figures 3C-3D, 4C-4D and 3C1-3D1, 4C1-4D1), the entire area of the defect was completely filled with Bio-Oss™ particles, allowing the appearance of fine bone trabeculae from the edge of the defect and overlapping in the region of the dura mater within 14 days. A more expressive formation of bone tissue was observed in the group treated with laser photobiomodulation therapy XS-PBM compared to the XS group.

In the subsequent period (42 days) there was an increase in the amount of bone tissue, intertwining the biomaterial, in a more organized configuration. The Bio-Oss™ particles were still very evident (red arrow). In some areas of the defect there was an absence of biomaterial and neoformed bone tissue in the XS-PBM group (yellow arrow). Some points of remodeled tissue were observed at the edges of the defect due to osteoclastic resorption.
Figure 3. Two-dimensional microtomographic images, (A-D) transaxial and (A1-D1) coronal sections, which demonstrate the repair of critical defects in calvaria, treated with clot (BC and BC-PBM) and biocomplex composed of Bio-Oss™ + fibrin biopolymer (XS and XS-PBM) within 14 days. Particles of the biomaterial (red arrow), thin trabeculae and newly formed bone tissue (yellow arrow).

Figure 4. Two-dimensional microtomographic images, (A-D) transaxial and (A1-D1) coronal sections, which demonstrate the repair of critical defects in calvaria, treated with clot (BC and BC-PBM) and biocomplex composed of Bio-Oss™ + fibrin biopolymer (XS and XS-PBM) within 42 days. Particles of the biomaterial (red arrow), thin trabeculae and newly formed bone tissue (yellow arrow).
Histomorphological observations
The repair occurred centripetally in all groups, with bone neoformation protruding from the margins to the center of the defect. It can be noted the absence of necrotic tissue, with the presence of bone cells and local neovascularization. There were no chronic inflammatory infiltrates with granuloma formation that characterized incompatibility of the grafted scaffolds with the recipient bed. Bone neoformation was partial, as indicated by the presence of areas without bone formation that were invaded by connective tissue. The neoformed bone matrix exhibited trabecular and mature characteristics, incorporating osteocytes derived from the differentiation of osteoblasts during the formation of the bone matrix.

Morphological comparison between groups in the period of 14 days

BC vs. BC-PBM
All defects showed bone repair compromised in restoring height, due to the collapse of the integument into the defect, and in the conformation of the newly formed bone, which was irregular along the dura mater. In the BC group, the area of the defect was predominantly filled with loose connective tissue with small loci of bone neoformation on the edge of the defect, however in the BC-PBM the defects were partially filled with immature bone and visible greater vascular proliferation (Figure 5).

XS vs. XS-PBM
The defects were filled with a large amount of biomaterial of irregular size and conformation, surrounded by connective tissue. The reparative bone neoformation remained restricted to the edge of the defect, but more discreet in the XS group in relation to the XS-PBM. In the central region of the defect in both groups, it was observed in the loose connective tissue, particles of the biomaterial permeated by inflammatory cells and collagen fibers with different orientations (Figure 5).

Morphological comparison between groups in the period of 42 days

BC vs. BC-PBM
At 42 days, in the BC group, the connective tissue formed filled the entire length of the defect, maintaining a thickness below that of the remaining bone and with less vascular formation,

![Figure 5. Histological images of critical size defects in rat calvaria within 14 days, coronal histological sections. (A) Blood clot group – BC; (B) blood clot with PBM group – BC-PBM; (C) xenogeneic bone graft + fibrin biopolymer scaffold group – XS; (D) xenogeneic bone graft + fibrin biopolymer scaffold with PBM group – XS-PBM. R: Remaining bone; TE: tegument; CT: connective tissue; BC: biocomplex biomaterial with fibrin biopolymer. B: Bio-Oss® particle; II: inflammatory infiltrate. Dotted yellow line: border; asterisk: bone neoformation; red dotted square: highlighted area; green arrow: osteocyte; blue arrow: blood vessel; black dotted circle: collagen fibers with scattered orientation. HE staining.](A-D) 4x lens, bar = 2 mm. (A’-D’) enlarged 40× images, bar = 100 µm.)
predominating in the region close to the bony edges. In the BC-PBM group, the defect was still filled with a large amount of connective tissue, showing a thin layer of bone tissue (asterisk) with diploid characteristics, and in some cases, they led to partial closure of the defect, but without recovery of your height (Figure 6).

**XS vs. XS-PBM**

In the panoramic aspect of the calvaria, an integrity of the defect height was observed due to the presence of the biomaterial and irregular border contour, resulting from the process of resorption of the graft particles, together with bone remodeling. In the XS group, there were also foci of inflammatory infiltrate mainly in the central area of the defect. However, in the XS-PBM group, the presence of inflammatory infiltrate was diffuse in the interstitium and less intense.

During this period, bone neoformation was also restricted to the defect margins, but more evident than at 14 days. There was a gradual reabsorption of the biomaterial and an increase in bone tissue at the edges of the defect and on the surface of the particles located in the most central areas of the defect in the XS-PBM group. In most of the slides analyzed, thin concentric layers of collagen fibers were formed around the graft particles, with a more organized direction in the XS-PBM group (Figure 6).

**Histomorphometry of the newly formed bone**

At 14 days, there was a higher percentage of new bone formed in the XS-PBM group compared to the other groups, the difference being statistically significant (Figure 7A and Table 2). In the period of 42 days, the groups biostimulated with laser (BC-PBM and XS-PBM) had the highest averages, but with no significant difference between them. However, they showed a statistically significant difference in relation to their respective groups without photobiomodulation (BC and XS). There was no significant difference between XS-PBM and BC (Figure 7B and Table 2).

When bone formation was evaluated within the same group comparatively in the two experimental periods, a significant difference was observed between 14 and 42 days in all groups except BC. However, in 42 days, all had the highest averages of new bone formed (Figure 7C and Table 2).

**Discussion**

This experimental protocol aimed to evaluate the repair of critical bone defects in rat calvaria using the association of two scaffolds forming a biocomplex - a xenogenic biomaterial widely used in regenerative medicine (Bio-Oss™) and the heterologous fibrin...
Table 2. Percentage of new bone formation in each group in the two experimental periods (14 and 42 days).

|          | 14 Days | 42 Days | p Value |
|----------|---------|---------|---------|
| BC       | 5.89 ± 0.85 bA | 7.06 ± 1.10 bcA | 0.1256  |
| BC-PBM   | 8.93 ± 1.42 aB | 11.22 ± 2.10 aA | 0.04086 |
| XS       | 4.31 ± 0.49 bB | 5.82 ± 0.73 cA | 0.02254 |
| XS-PBM   | 6.01 ± 1.42 bB | 9.47 ± 1.45 abA | 0.01093 |

BC: blood clot group; BC-PBM: blood clot with PBM group; XS: xenogeneic bone graft + fibrin biopolymer scaffold group; XS-PBM: xenogeneic bone graft + fibrin biopolymer scaffold with PBM group.

Different lowercase letters (column, a ≠ b ≠ c) indicate a significant difference in the same period between groups (ANOVA and Tukey). Different capital letters (line, A ≠ B) indicate a significant difference in each group in the two periods (unpaired t-test). Values defined as the mean ± standard deviation (p ≤ 0.05).

Figure 7. Volume density of new bone formed (%) in the different groups tested (BC, BC-PBM, XS, XS-PBM) in the periods of (A) 14 and (B) 42 days; ANOVA followed by Tukey’s post-test (p ≤ 0.05). (C) Volume density of new bone formed (%) in each group tested in the evaluated periods (14 and 42 days); Student’s t test (p ≤ 0.05). Different letters (A ≠ B ≠ C) indicate a significant difference (p ≤ 0.05).

Bone defects can occur due to various clinical situations and their reconstruction is a necessary and important step to reestablish the morphological, functional and mechanical integrity of the compromised bone, aiming at the patient’s rehabilitation [46]. Extensive bone injuries may have their potential for spontaneous regeneration compromised and leads to the search for the development of new osteosubstitute materials and three-dimensional bioadegradable scaffolds [1,47–49]. One of the most used experimental models in this area is the realization of critical defects in calvaria [50,51]. Critical defects can evolve to non-atrophic union due to the nature of the fracture, with impaired vascularity and soft tissue injury and will always require treatment of the defect [52].

In this experiment, it was observed in all groups, through transaxial and coronal microtomographic analysis, that the repair process with the formation of new bone, with radiopaque aspect in the images, occurred centripetally, from the margins of the surgical wound and the dura mater underlying. The evaluation was carried out qualitatively, since it becomes difficult to quantify with the presence of the graft, due to the similarity of radiopacity between the biomaterial and the new bone formed [53–55]. In addition, in this study, we chose to quantify new bone formed on histological slides, which allows greater precision in morphometry, avoiding conflicting and inadequate data [56,57].

During the post-surgical period of this experimental protocol, the defect treated by blood clot obtained from the animal itself through intracardiac puncture (groups BC and BC-PBM) did not completely close, being filled only by a thin bone layer on
the surface of the dura mater, occupying 7.06 ± 1.10 and 11.22 ± 2.10 percent of the volume of the defects, respectively, at 42 days. Thus, the defect of 8 mm in diameter in the calvaria of rats was not able to repair spontaneously with only a blood clot and can be considered as a critical defect, in agreement with other similar experiments [55,58,59].

Histomorphometrically, at 14 days, the BC-PBM group showed the highest percentage of new bone formation (8.93 ± 1.42) with a significant difference in relation to the BC, XS and XS-PBM groups (5.89 ± 0.85, 4.31 ± 0.49 e 6.01 ± 1.42, respectively). All material grafted into a surgical cavity, even though it is biocompatible, generates an inflammatory response at the host site [9,60]. Biomaterials, after their implantation, delay bone deposition around the particles, being directly proportional to the reabsorption [61,62]. In addition, the PBM effects in the first days of its application, such as reducing the inflammatory response, can contribute to accelerating bone formation [37,63–66].

In the 42-day postoperative period, the BC-PBM and XS-PBM groups had a higher percentage of new bone deposition, with a significant difference in relation to the groups with the same treatment (11.22 ± 2.10 and 9.47 ± 1.45, respectively) and without PBM (BC 7.06 ± 1.10 and XS 5.82 ± 0.73, respectively). This fact occurs, among several biomodulatory benefits of LLLT, through the improvement in the lamellar organization of collagen fibers, increased bone cellularity, decreased inflammatory infiltrate and, thus, generate conditions for higher averages of neoformed bone [29,42,67–70].

When comparing the evolution of the repair process, within the same group, between the periods of 14 and 42 days, only the BC group did not show a significant difference (5.89 ± 0.85 and 7.06 ± 1.10, respectively). In general, due to the rapid reabsorption of the blood clot in the first days, there is the possibility of collapse/invansion of adjacent soft tissues that started to occupy the space of surgical defects. The insertion of the xenogenic biomaterial, mainly with the association of another three-dimensional scaffold such as the fibrin biopolymer, creates a structured microenvironment, mainly in the central area of the defects, which prevents the invasion of soft tissues and may even reduce the need for guided bone regeneration procedures, with the addition of membranes to cover the defect [20,29,71–74].

The surgical cavities in which the fibrin biopolymer (XS and XS-PBM groups) were used showed intense angiogenesis as early as 14 days, as well as the occasional presence of granulation tissue and the permanence of vascular spaces at 42 days [75]. This biological response demonstrates that the biopolymer is biocompatible, in agreement with previous studies [31,76,77], because in addition to not having a foreign body reaction, it favored the insertion in the surgical bed, the deposition and proliferation of osteoblastic cells, functioning as a scaffold for bone regeneration [78–82].

It can also be highlighted the binding function of the fibrin biopolymer, since in its use with the Bio-Oss™ particles, it allowed the permanence in the implantation site forming multiple layers. As the biomaterials particulate in granules can be easily displaced from the surgical bed, even by the action of the local bleeding itself, it allows the use of these agents to be inducted with the purpose of forming a firm and mechanically stable network, with good adhesive properties [22,26,82]. The clinical applicability and benefits of commercially available fibrin sealants, derived from human blood, for soft tissues are well documented, but their contribution to bone surgery and oral and periodontal surgery remains controversial [83].

Finally, snake venom purified fibrin biopolymer is the only totally heterologous sealant in the world, with several beneficial properties in multiple areas of regenerative medicine. It has a low production cost, has proven to be clinically safe and effective in the treatment of chronic venous ulcers, and, through pre-clinical research carried out, a great potential for clinical applications such as scaffolding and drug delivery systems is foreseen [27,34,38,82,84–89]. The idea of using a biocomplex associated with PBM therapy by our research group opens a new opportunity to develop an innovative therapy to treat critical-size defects.

**Conclusion**

In view of the results obtained, it can be seen that the defects treated with PBM therapy using an 830 nm wavelength laser allowed an improvement in the formation of new bone. This suggests that there was a biomodulation of the inflammatory process, with more organized deposition of collagen fibers in the defect area and consequently, a more homogeneous bone conformation.

Therefore, the filling with the biocomplex formed by the association of the fibrin biopolymer and xenogenic graft favored the insertion and permanence of the particulate material in the critical size defect performed in the calvaria of rats, creating a favorable microenvironment for an adequate repair process as an innovative drug delivery system.

**Availability of data and materials**

The data generated and analyzed during the current study are available from the corresponding author upon reasonable request.

**Funding**

This study was financed in part by the Brazilian Coordination for the Improvement of Higher Education Personnel (CAPES) – Finance Code 001. RSFJ is CPNq research fellow Proc 303224/2018-5.

**Competing interests**

Benedito Barraviera and Rui Seabra Ferreira Jr., authors of this article, are respectively emeritus editor and editor-in-chief of the *Journal of Venomous Animals and Toxins including Tropical Diseases*. They did not get involved in the peer review process of this manuscript. Bio-Oss™ was assigned for the present research by Geistlich Pharma AG (Wolhusen, Switzerland; Ministry of Health Registration No: 806.969.30002). The fibrin
biopolymer was provided by the Center for the Study of Venoms and Venomous Animals (CEVAP), São Paulo State University (UNESP), Botucatu, SP, Brazil.

Authors' contributions

DVB, KTP, CHBR, CRPD and CRSB performed the surgical procedures, euthanasia, acquisition and material processing, analysis and interpretation of data. JCA helped with histological analysis. MAHD and MPA performed micro-CT scan and image processing on specific softwares. BB and RSFJ contributed to the supply of fibrin biopolymer, study design and manuscript review. DdBt and ACA contributed to the performance of statistical analyzes. RLb contributed to the design of the study, analysis and interpretation of data. All authors revised the manuscript to important intellectual content. All of the authors have read and approved the manuscript.

Ethics approval

The study was approved by the Ethics Committee on Teaching and Research in Animals of the Bauru School of Dentistry, University of São Paulo (FOB-USP), Brazil, Protocol CEEPA n. 019/2016, dated October 21, 2016.

Consent for publication

Not applicable.

References

1. Abou Nee EA, Chrzanowski W, Salih VM, Kim HW, Knowles JC. Tissue engineering in dentistry. J Dent. 2014 Aug;42(8):915–28.
2. Tamaddon M, Samizadeh S, Wang L, Blunn G, Liu C. Intrinsic osteoinductivity of Porous Titanium Scaffold for Bone Tissue Engineering. Int J Biomater. 2017 Jul 26;2017.
3. Campana V, Milano G, Pagano E, Barba M, Cicione C, Salonna G, Lattanzi W, Logroscino G. Bone substitutes in orthopaedic surgery: from basic science to clinical practice. J Mater Sci Mater Med. 2014 Oct 25(10):2245–61.
4. Wang W, Yeung KWK. Bone grafts and biomaterial substitutes for bone defect repair: A review. Bioact Mater. 2017 Jun 7;2(4):224–47.
5. Giannoudis PV, Dinopoulos H, Tsiridis E, Jones E, Einhorn TA. Bone engineering in dentistry. J Dent. 2014 Aug;42(8):915–28.
6. Giannoudis PV, Jones E, Cinquin L. Adhesive and sealant interfaces for general surgery applications. Adhesive and sealant interfaces for general surgery applications. J Biomed Mater Res B Appl Biomater. 2016 Apr;104(3):626–50.
7. Melek LN. Tissue engineering in oral maxillofacial reconstruction. Tanta Dent J. 2015 Sep;12(3):211–23.
8. Melek LN. Tissue engineering in oral and maxillofacial reconstruction. Tanta Dent J. 2015 Sep;12(3):211–23.
9. Pomin K, Cestari M, German I, Rosso M, Gonçalves J, Buchaim D, Pereira M, Andreo JC, Rosa Jr GM, Coletta BBD, Shindo JVTC, Buchaim RL. Influence of acidic fibroblast growth factor on bone regeneration in experimental cranial defects using spongostan and Bio-Oss® as traditional carriers. J Craniofac Surg. 2013 Sep;24(5):1507–14.
10. Noda A, Sato A, Maruyama Y, Matsushita M, Fujita H. Bio-Oss® and commercial fibrin-mixed Bio-Oss® : An experimental study. J Cranio-maxillofac Surg. 2014 Jun;42(4):e47–50.
11. Kim B, Kim S, Kim S, Lim SC, Kim YK. A comparison of bone generation capability in rabbits using tooth ash and plaster of Paris with platelet-rich plasma or fibrin sealant. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010 Sep;110(3):e8–14.
12. Chen K, Shyu P, Dong G, Chen Y, Kuo W, Yao C. Biomaterials Reconstruction of calvarial defect using a tricalcium phosphate-oligomeric proanthocyanidins cross-linked gelatin composite biomaterials. 2009;30:1682–8.
13. Kim Y, Kim S, Yun P, Yeo IS, Jin SC, Oh JS, Kim HJ, Yu SK, Lee SY, Kim JS, Um IW, Jeong MA, Kim GW. Autogenous teeth used for bone grafting: a comparison with traditional grafting materials. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014 Jan;117(1):e39–45.
14. Arias-Gallo J, Chamorro-Pons M, Avendaño C, Giménez-Gallego G. Influence of acidic fibroblast growth factor on bone regeneration in experimental cranial defects using spongostan and Bio-Oss as traditional carriers. J Craniofac Surg. 2013 Sep;24(5):1507–14.
15. Fernández-Medina E, Dedossi G, Asencio V, Fernández-Domínguez M, Gehrke S, Aragoneses J, Calvo-Guirado JL. Comparison of different bone filling materials and resorbable membranes by means of micro-tomography. A preliminary study in Rabbits. Materials (Basel). 2019 Apr 12;12(8):1197.
16. Jokanović V, Čolović B, Marković D, Petrović M, Soldatović I, Antonijević D, Milosavljević P, Sjerobab N, Supta J. Extraordinary biological properties of a new calcium hydroxyapatite/poly(lactide-co-glycolide)-based scaffold confirmed by in vivo investigation. Biomed Tech. 2017 Jun 10;62:295–306.
17. Lorenzo J, Al-Maawi S, Sader R, Ghanaati S. Individualized titanium mesh combined with platelet-rich fibrin and deproteinized bovine bone: A new approach for challenging augmentation. J Oral Implantol. 2018 Oct;44(5):345–50.
18. Xuan F, Lee J, Son J, Jeong S, Choi B. A comparative study of the regenerative effect of sinus bone grafting with platelet-rich f: brin mixed Bio-Oss® and commercial fibrin-mixed Bio-Oss® : An experimental study. J Cranio-maxillofac Surg. 2014 Jun;42(4):e47–50.
19. Kim B, Kim S, Kim S, Lim SC, Kim YK. A comparison of bone generation capability in rabbits using tooth ash and plaster of Paris with platelet-rich plasma or fibrin sealant. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010 Sep;110(3):e8–14.
20. Pomin KT, Buchaim DV, Andreo JC, Rosso MP de O, Della Coletta BB, German IJS, Biguetti ACC, Shinohara AL, Rosa Jr GM, Shindo JVTC, Alcalde MP, Duarte MAH, Teixeira DB, Buchaim RL. Fibrin sealant derived from human plasma as a scaffold for bone grafts associated with photobiomodulation therapy. Int J Mol Sci. 2019 Apr;20(7):1761.
21. Agarwalla A, Puzzitiello R, Garcia G, Forsythe B. Application of a Beta-Tricalcium Phosphate Graft to Minimize Bony Defect in Bone-Patella Tendon-Bone Anterior Cruciate Ligament Reconstruction. Arthrosc Tech. 2018 Jun;11(7):e725–9.
22. Scognamiglio F, Traván A, Rustighi I, Tarchi P, Palmisano S, Manzini D, Paoletti S. Adhesive and sealant interfaces for general surgery applications. J Biomed Mater Res B Appl Biomater. 2016 Apr;104(3):626–39.
23. Mangano C, Paino F, d`Aquino R, de Rosa A, Iezzi G, Piattelli A, Laino L, Mifsudis T, Desiderio V, Mangano F, Papaccio G, Tirino V. Human Dental Pulp Stem Cells hook into Biocoral scaffold forming an engineered biocomplex. PLoS One. 2014(6);9(6):e18721.
24. Nakamura K, Koshino T, Saito T. Odontogenic response of the rabbit femur to a hydroxyapatite thermal decomposition product—fibrin glue mixtures. Biomaterials. 1998 Oct;19(20):3–9.
25. Noori A, Ashrafi SJ, Vaez-Ghaemi R, Hatamian-Zaremi A, Webster T. A review of fibrin and fibrin composites for bone tissue engineering, Int J Nanomedicine. 2017 Jul 12;12:4937–49.
26. Brown A, Barker T. Fibrin-based biomaterials: Modulation of macroscopic properties through rational design at the molecular level. Acta Biomater. 2014 Apr;10(4):1502–14.
27. Barros LC, Ferreira JR RS, Barriavera SRS, Stoof HO, Thomazini-Santos IA, Mendes-Giannini MJ, Torcano E, Barriavera B. A new fibrin sealant derived from cotrous durissus terrificus venom: Applications in medicine. J Toxicol Environ Health B Crit Rev. 2009 Oct;12(8):553–71.
28. Buchaim DV, Cassaro CV, Shindo JVTC, Coletta BB Della, Pomin KT, De Oliveira Rosso MP, Campos LMG, Ferreira JR RS, Barriavera B, Buchaim RL. Unique heterologous fibrin biopolymer with hemostatic, adhesive, sealant, scaffold and drug delivery properties: A systematic review. J Venom Anim Toxins incl Trop Dis. 2019;25:1–15. https://doi.org/10.1590/1678-9199-JVATITD-2019-0038.
29. Della Coletta BB, Jacob TB, Moreira LA de C, Pomin KT, Buchaim DV, Eleuterio RG, Pereira ESBM, Roque DD, Rosso MPO, Shindo JVTC, Duarte MAH, Ferreira JR RS, Barriavera B, Dias JA, Andreo IA, Mendes-Giannini MJS, Torcano E, Barriavera B. A new fibrin sealant derived from cotrous durissus terrificus venom: Applications in medicine. J Toxicol Environ Health B Crit Rev. 2009 Oct;12(8):553–71.
Buchaim et al. J Venom Anim Toxins incl Trop Dis, 2022, 28:e20210056

Page 13 of 14

38.  Rosso MP de O, Rosa Júnior GM, Buchaim DV, German IJS, Pomini KT, de Souza RG, Pereira M, Favaretto Jr IA, Bueno CRS, Gonçalves JBO, Buchaim JR JS, Barraviera B, Andreo JC, Buchaim RL. Stimulation of morphofunctional repair of the facial nerve with photobiomodulation, using the end-to-side technique or a new heterologous fibrin sealant. J Photochem Photobiol B. 2017 Oct;175:20–8.

39.  Buchaim DV, Rodrigues AC, Buchaim RL, Barraviera B, Ferreira Júnior RS, Rosa Júnior GM, Bueno CRS, Roque DD, Dias DV, Dare LR, Andreo JC. The new heterologous fibrin sealant in combination with low-level laser therapy (LLLT) in the repair of the buccal branch of the facial nerve. Lasers Med Sci. 2016 Jul;31(5):965-72.

40.  Weibel ER. Stereological Principles for Morphometry in Electron Microscopic Cytology. Int Rev Cytol. 1969:26:235–302.

41.  de Oliveira Gonçalves JB, Buchaim DV, de Souza Bueno CR, Pomini KT, Barraviera B. Fibrin biopolymer as scaffold candidate to treat bone defects in rats. J Venom Anim Toxins incl Trop Dis. 2019;25:1–17. https://doi.org/10.1590/1678-9199-JVATITD-2019-0007.

42.  Pinto CG, Leite APS, Sartori AA, Tibúrcio FC, Barraviera B, Ferreira Jr RS, Filadelpho AL, Carvalho SC, Matheus SMM. Heterologous fibrin biopolymer incorporated to a single suture stitch enables the return of neuromuscular junction to its mature pattern after peripheral nerve injury. Injury. 2020 Apr 1;52(4):731-7.

43.  Venante HS, Chappuis-Chocano AP, Marcilio-Toala OO, Da Silva RA, Da Costa RB, Depeus MD, Barraviera B, Ferreira Jr RS, Lara VS, Neielenbraak KH, Honório HM, Porto VC. Fibrin biopolymer incorporated with antimicrobial agents: a proposal for coating denture bases. Materials (Basel). 2021;14(7):1-14.

44.  Abbade LPF, Barraviera SRCs, Silvares MRC, Lima ABB d, C. Haddad GR, Gatti MAN, Medolago NB, Carneiro MTR, Santos LD, Ferreira Jr RS, Barraviera B. Treatment of Chronic Venous Ulcers With Heterologous Fibrin Sealant: A Phase IIIII Clinical Trial. Front Immunol. 2021 Feb 23;12:627541.

45.  Abbade LPF, Ferreira Jr RS, Santos LD dos, Barraviera B. Chronic venous ulcers: a review on treatment with fibrin sealant and prognostic advances using proteomic strategies. J Venom Anim Toxins incl Trop Dis. 2020;26:1– 11. https://doi.org/10.1590/1678-9199-JVATITD-2019-0101.

46.  Bayat M, Virdi A, Jalali R, Rezaei F. Comparison of effects of LLLT and LIPUS on fracture healing in animal models and patients : A systematic review. Prog Biophys Mol Biol. 2018 Jan;132:3-22.

47.  Escudero JSB, Perez MGB, de Oliveira Rosso MP, Buchaim DV, Pomini KT, Campos LMG, Audi M, Buchaim RL. Photobiomodulation therapy (PBMT) in bone repair: A systematic review. Injury. 2019 Nov;50(11):1853–67.

48.  Ferreira RS, de Barros LC, Abbade LPF, Barraviera SRCs, Silvares MRC, de Pontes LG, Santos LD, Barraviera B. Heterologous fibrin sealant derived from snake venom: From bench to bedside - an overview. J Venom Anim Toxins incl Trop Dis. 2017;23:1–12. https://doi.org/10.1186/s40409-017-0109-8.

49.  Santos L, Oliveira C, Vasconcelos BM, Vilela D, Melo L, Ambrósio L, da Silva A, Murbarb L, Kurissio J, Cavalcante J, Cassaro CV, Barros L, Barraviera B, Ferreira Jr RS. Good management practices of venous ulcers in captivity to produce biological venom-based medicines: achieving replicability and contributing to pharmaceutical industry. J Toxicol Environ Health B Crit Rev. 2021 Jan 22;14(1):30–50.

50.  Buchaim DV, Andreo JC, Ferreira Junior RS, Barraviera B, De Castro Rodrigues A, Macedo MC, Rosa Jr GM, Shinhora AL, German IJS, Pomini KT, Buchaim RL. Efficacy of Laser Photobiomodulation on Morphological and Functional Repair of the Facial Nerve. Photomed Laser Surg. 2017 Aug;35(8):442–9.

51.  de Oliveira Gonçalves JB, Buchaim DV, de Souza Bueno CR, Pomini KT, Barraviera B, Ferreira Jr RS, Andreo JC, Rodrigues AC, Cestari TM, Buchaim RL. Effects of low-level laser therapy on autogenous bone graft stabilized with a new heterologous fibrin sealant. J Photomedat Photobiol B. 2016 Sep;162:663–8.

52.  de Oliveira Rosso MP, Oyadomari AT, Pomini KT, Coletta BB Della, Shindo JVTC, Júnior RSF, Barraviera B, Buchaim DV, Teixeira DB, Barbalho SM, Alcalde, MP, Duarte MAH, Andreo JC, Buchaim RL. Photobiomodulation therapy associated with heterologous fibrin biopolymer and bovine bone matrix helps to reconstruct long bones. Biomolecules. 2020 Mar 2;10(3):383.

53.  Rosso MP de O, Rosa Júnior GM, Buchaim DV, German IJS, Pomini KT, de Souza RG, Pereira M, Favaretto Jr IA, Bueno CRS, Gonçalves JBO, Barraviera B, Andreo JC, Buchaim RL. Photobiomodulation Therapy on the Guided Bone Regeneration Process in Defects Filled by Biphasic Calcium Phosphate Associated with Fibrin Biopolymer. Molecules. 2021 Feb 5;26(4):847.

54.  Creste CFZ, Orsi PR, Landim-Alvarenga FC, Justulin LA, Golim MA, Barraviera B, Ferreira Jr RS. Highly Effective Fibrin Biopolymer Scaffold for Stem Cells Upgrading Bone Regeneration. Materials (Basel). 2020 Jun 17;13(12):2747.

55.  Cassaro CV, Justulin LA, De Lima PR, De Assis Golim M, Biscola NP, De Castro MV, Oliveira ALR, Doiche DP, Pereira EJ, Ferreira Jr RS, Barraviera B. Fibrin biopolymer as scaffold candidate to treat bone defects in rats. J Venom Anim Toxins incl Trop Dis. 2019;25:1–7. https://doi.org/10.1590/1678-9199-JVATITD-2019-0007.

56.  Pinto CG, Leite APS, Sartori AA, Tibúrcio FC, Barraviera B, Ferreira Jr RS, Filadelpho AL, Carvalho SC, Matheus SMM. Heterologous fibrin biopolymer incorporated to a single suture stitch enables the return of neuromuscular junction to its mature pattern after peripheral nerve injury. Injury. 2020 Apr 1;52(4):731-7.
61. Morais JM, Papadimitrakopoulos F, Burgess DJ. Biomaterials / Tissue Interactions: Possible Solutions to Overcome Foreign Body Response. 2010 Jun;12(2):188–96.

62. Klopfleisch R, Jung F. The pathology of the foreign body reaction against biomaterials. J Biomed Mater Res A. 2017 Mar;105(3):927–40.

63. Kazancioglu HO, Ezirganli S, Aydin MS. Effects of Laser and Ozone Therapies on Bone Healing in the Calvarial Defects. 2013 Nov;24(6):2141–6.

64. Marques L, Holgado L, Francischone L, Ximenez J, Okamoto R, Kinoshita A. New LLRT protocol to speed up the bone healing process-histometric and immunohistochemical analysis in rat calvarial bone defect. Lasers Med Sci. 2015 May;30(4):1223–30.

65. de Deco CP, da Silva Marchini AMP, Marchini L, da Rocha RF. Extended Periods of Alcohol Intake Negatively Affects Osseointegration in Rats. J Oral Implantol. 2015 Jun;41(3):e44-9.

66. de Oliveira LSS, de Araújo AA, de Araújo Junior RF, Barboza CAG BB, Silva JP. Low-level laser therapy ( 780 nm ) combined with collagen sponge scaffold promotes repair of rat cranial critical-size defects and increases TGF-β, FGF-2, OPG / RANK and osteocalcin expression. Int J Exp Pathol. 2017 Apr;98(2):75–85.

67. de Almeida ALPF, Medeiros IL, Cunha MJS, Sbrana MC, de Oliveira PGFP, Esper LA. The effect of low-level laser on bone healing in critical size defects treated with or without autogenous bone graft: An experimental study in rat calvaria. Clin Oral Implants Res. 2014 Oct;25(10):1131–6.

68. Bosco AF, Faleiros PL, Carmona LR, García VG, Theodoro LH, de Araújo NJ, Nagata MJH, Almeida JM. Effects of low-level laser therapy on bone healing of critical-size defects treated with bovine bone graft. J Photochem Photobiol B. 2016 Aug;163:303–10.

69. de Oliveira Gonçalves JB, Buchaim DV, de Souza Bueno CR, Pomini KT, Barraviera B, Ferreira Júnior RS, Andreo JC, Rodrigues AC, Cestari TM, Buchaim RL. Effects of low-level laser therapy on autogenous bone graft stabilized with a new heterologous fibrin sealant. J Photochemistry Photobiol B. 2016 Sep;162:663–8.

70. Rosso MPO, Buchaim DV, Pomini KT, Coletta BB Della, Reis CBH, Pilon JPEG, Duarte Jr G, Buchaim RL. Photobiomodulation therapy (PBMT) applied in bone reconstructive surgery using bovine bone grafts: A systematic review. Materials (Basel). 2019 Dec 5;12(24):4051.

71. Kneser U, Stangenberg L, Ohnolz J, Buettern J, Stenzel T, Stangenberg L, Stangenberg L. Evaluation of processed bovine cancellous bone matrix seeded with syngenic osteoblasts in a critical size calvarial defect rat model. J Cell Mol Med. 2006 Jul-Sep;10(4):695–707.

72. Mokbel N, Bou Serhal C, Matri G, Naaman N. Healing patterns of critical size bony defects in rat following bone graft. Oral Maxillofac Surg. 2008 Jul-Aug;12(2):73–8.

73. Kitayama S, Wong LO, Ma L, Hao J, Kasugai S, Lang NP, Mattheos N. Interactions: Possible Solutions to Overcome Foreign Body Response. J Venom Anim Toxins incl Trop Dis. 2019;25. https://doi.org/10.1590/1678-9199-JVATITD-2019-0038.

74. Mozafari R, Kryylenko S, Castro MV, Ferreira RS, Barraviera B, Oliveira ALR. Combination of heterologous fibrin sealant and bioengineered human embryonic stem cells to improve regeneration following autogenous sciotic nerve grafting repair. J Venom Anim Toxins incl Trop Dis. 2020 Apr;12:1–11. doi:10.1186/s40409-018-0147-x.

75. State P, Barraviera SRCs, State P, Silvesrs MR, Satate P A new fibrin sealant derived from snake venom canindic to treat chronic venous ulcers. J Acad Dermatol. 2015 May;1:72(5):A8271.

76. Rahal SC, Amaral MSP, Pai DV, Barraviera SRCs, Caporal EH., Croco AJ. Effect of fibrin glue derived from snake venom on the viability autogenous split-thickness skin graft. J Venom Anim Toxins incl Trop Dis. 2004;10:161–72. https://doi.org/10.1590/S1678-91992004000200006.

77. latecola A, Barraviera B, Ferreira Júnior RS, dos Santos GR, Neves JL, da Cunha MR. Use of a new fibrin sealant and laser irradiation in the repair of skull defects in rats. Braz Dent J. 2013 Sep-Oct;24(5):456–61. de Oliveira CTB, Leonel BC, de Oliveira AC, de Brito Paiva M, Ramos J, Barraviera B, Ferreira JR RS, Shimano AC. Effects of fibrin sealant and bone fragmentation on defect regeneration performed on rat tibiae: An experimental study. J Mech Behav Biomed Mater. 2020 Apr;104:103662.

78. Creste CFZ, Orsi PR, Landim-Alvarenga FC, Justulin LA, Golim M de A, Barraviera B, Ferreira JR S. Highly Effective Fibrin Biopolymer Scaffold for Stem Cells Upgrading Bone Regeneration. Materials (Basel). 2020 Jun 17;13(12):2747.

79. Orsi PR, Landim-Alvarenga FC, Justulin LA, Kaneno R, De Assis Golim M, Dos Santos DC, Creste CFZ, Oba E, Maia L, Barraviera B, Ferreira JR S. A unique heterologous fibrin sealant (HFS) as a candidate biological scaffold for mesenchymal stem cells in osteoporotic rats. Stem Cell Res Ther. 2017 Sep 29;8(1):1–14.

80. Gasparotto VPO, Landim-Alvarenga FC, Oliveira ALR, Simões GF, Lima-Neto JF, Barraviera B, Ferreira JR S. A new fibrin sealant as a three-dimensional scaffold candidate for mesenchymal stem cells. Stem Cell Res Ther. 2014 Jun 10;5.

81. Rodríguez-Sánchez DN, Pinto GBA, Cartarozzi LP, de Oliveira ALR, Bovolato ALC, de Carvalho M, Silva JVL, Dernowska J, Golim M, Barraviera B, Ferreira Jr RS, Deffune E, Bertanha M, Amorim RM. 3D-printed nerve guidance conduits multi-functionalized with canine multipotent mesenchymal stromal cells promote neuroregeneration after sciatic nerve injury in rats. Stem Cell Res Ther. 2021 May 29;12(1):303.

82. Soffer E, Ouhayoun JP, Anagnostou F. Fibrin sealants and platelet preparations in bone and periodontal healing. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003 May;95(5):521–8.

83. Buchaim DV, Cassaro CV, Shinodo JVTC, Coletta BDD, Pomini KT, De Oliveira AM, Campos LMG, Ferreira Jr RS, Barraviera B, Buchaim RL. Unique heterologous fibrin biopolymer with hemostatic, adhesive, sealant, scaffold and drug delivery properties: A systematic review. J Venom Anim Toxins incl Trop Dis. 2019;25. https://doi.org/10.1590/1678-9199-JVATITD-2019-0038.

84. Mozafari R, Kryylenko S, Castro MV, Ferreira RS, Barraviera B, Oliveira ALR. Combination of heterologous fibrin sealant and bioengineered human embryonic stem cells to improve regeneration following autogenous sciotic nerve grafting repair. J Venom Anim Toxins incl Trop Dis. 2018 Apr;12:1–11. doi:10.1186/s40409-018-0147-x.

85. State P, Barraviera SRCs, State P, Silvares MR, Satate P A new fibrin sealant derived from snake venom candidate to treat chronic venous ulcers. J Acad Dermatol. 2015 May;1:72(5):A8271.

86. Rahal SC, Amaral MSP, Pai DV, Barraviera SRCs, Caporal EH., Croco AJ. Effect of fibrin glue derived from snake venom on the viability autogenous split-thickness skin graft. J Venom Anim Toxins incl Trop Dis. 2004;10:161–72. https://doi.org/10.1590/S1678-91992004000200006.

87. Biscola NP, Cartarozzi LP, Uliaen-Benitez S, Barbizan R, Castro MV, Spejo AB, Ferreira Jr RS, Barraviera B, Oliveira ALR. Multiple uses of fibrin sealant for nervous system treatment following injury and disease. J Venom Anim Toxins incl Trop Dis. 2017;23:1–11. doi:10.1186/s40409-017-0103-0.

88. Gatti MAN, Vieira LM, Barraviera B, Barraviera SRCS. Treatment of venous ulcers with fibrin sealant derived from snake venom. J Venom Anim Toxins incl Trop Dis. 2011;17:226–9. https://doi.org/10.1590/S1678-91992011000200015.